Valdoxan® today received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with Major Depressive Episodes (MDE).1 Valdoxan is an innovative approach to the treatment of MDE and has demonstrated convincing efficacy in depressed patients with moderate-severe depression2, offering new hope to many of the more than 2.
Popularity: 1% [?]
Related posts:
- Valdoxan(R) Granted Marketing Authorisation For The Treatment Of Major Depressive Episodes In Europe
- New Melatonergic Antidepressant Combines Efficacy With Very Favourable Side-Effect Profile
- New Melatonergic Antidepressant Combines Efficacy With Very Favourable Side-Effect Profile
- FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
- FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
Comments
No Responses to “Novel Antidepressant Valdoxan(R), Receives EMEA CHMP Positive Opinion For Major Depressive Episodes”